GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » PS Ratio

BetterLife Pharma (XCNQ:BETR) PS Ratio : (As of Dec. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BetterLife Pharma's share price is C$0.11. BetterLife Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jul. 2024 was C$0.00. Hence, BetterLife Pharma's PS Ratio for today is .

The historical rank and industry rank for BetterLife Pharma's PS Ratio or its related term are showing as below:

XCNQ:BETR's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.69
* Ranked among companies with meaningful PS Ratio only.

BetterLife Pharma's Revenue per Sharefor the three months ended in Jul. 2024 was C$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jul. 2024 was C$0.00.

Back to Basics: PS Ratio


BetterLife Pharma PS Ratio Historical Data

The historical data trend for BetterLife Pharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma PS Ratio Chart

BetterLife Pharma Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BetterLife Pharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BetterLife Pharma's PS Ratio

For the Biotechnology subindustry, BetterLife Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's PS Ratio falls into.



BetterLife Pharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

BetterLife Pharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.11/0
=

BetterLife Pharma's Share Price of today is C$0.11.
BetterLife Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


BetterLife Pharma  (XCNQ:BETR) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


BetterLife Pharma PS Ratio Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Steven Sangha 10% Security Holder
Ahmad Doroudian Director, Senior Officer
Robert Metcalfe Director
James Russell Starr Senior Officer